Muyuan Foods, the largest pig producer in China, has chosen to set the price for its Hong Kong share sale at the top of the marketed range. The company is offering 274 million H shares at HK$39 per share, a move that would raise approximately HK$10.69 billion, equivalent to about $1.37 billion based on the exchange rate of $1 = 7.8109 Hong Kong dollars.
Company filings indicate that Muyuan expects to publish the allocation results on February 5. The newly issued shares are slated to start trading on the Hong Kong Stock Exchange on February 6, according to the same regulatory disclosure.
The offering is sizable by this year’s standards in Hong Kong - one of the larger deals so far - and comes at a time when China’s pork sector is facing headwinds. The company’s share sale coincides with reports of a pork surplus in the domestic market tied to weak consumer demand and a slowing economy, dynamics that have exerted downward pressure on prices and reduced margins for farmers.
Muyuan has specified that the net proceeds from the share sale will be directed to research and development. The stated priorities are breeding, smart farming, nutrition management and biosecurity. These investments are presented as the company’s strategy for deploying the funds raised through the listing.
Key operational milestones for the transaction are explicit in the regulatory filing: the company will report how shares are allocated on February 5, and investors can expect the shares to make their market debut on February 6. The filing reiterates the offer price and the number of H shares placed in the Hong Kong offering.
Market observers will be watching how the deal proceeds against a backdrop of softer pork demand and price pressure. For Muyuan, the capital raised is earmarked for targeted R&D initiatives rather than for broader uses, with emphasis on technological and biological measures aimed at production and herd health.
With the offering positioned at the top end of the indicated range, Muyuan appears to be seeking to maximize capital raised from public investors while moving forward with a focused research agenda in agricultural production and biosecurity measures.